RxDoctor Payments Data

Dominick Trapani, DO

Family Medicine · Raleigh, NCNPI 1124382130

Payments from drug & device makers

$2,356in general payments, 2019–2025

Across 154 payments — averaging $15.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$849
  • Lilly USA, LLC$270
  • Amgen$203
  • AstraZeneca$186
  • Boehringer Ingelheim$167
  • Johnson & Johnson$118
  • plus $563 from 14 others

What the payments were for

  • Food & beverage$2,34199%
  • Education$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,356 in reported general payments places this provider in the 80th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$70,959
Medicare patients
178
Services billed
924

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban61$76,519
OzempicSemaglutide43$51,862
JardianceEmpagliflozin60$50,209
TrulicityDulaglutide36$36,107
JanuviaSitagliptin Phosphate14$19,486
Tresiba Flextouch U-100Insulin Degludec17$13,635
FarxigaDapagliflozin Propanediol25$13,394
MounjaroTirzepatide12$12,471
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$11,063
MyrbetriqMirabegron14$9,439
LinzessLinaclotide17$8,901
Breo ElliptaFluticasone/Vilanterol16$5,959
Esomeprazole Magnesium25$3,438
Lantus SolostarInsulin Glargine,hum.Rec.Anlog28$3,422
Atorvastatin Calcium267$2,858

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$30$76,51961 claims
Novo NordiskOzempic$849$51,86243 claims
Boehringer IngelheimJardiance$167$50,20960 claims
Lilly USA, LLCTrulicity, Mounjaro$270$48,57748 claims
MerckJanuvia$32$19,48614 claims
GSKTrelegy Ellipta, Breo Ellipta$39$17,02228 claims
AstraZenecaFarxiga$186$13,39425 claims
AbbVieLinzess$57$8,90117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Raleigh

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →